The Harvard Severe Asthma Course 2026 by Brigham and Women’s Hospital is a comprehensive two-day CME program focused on the assessment and management of difficult-to-control asthma in both adult and pediatric patients.

This course provides in-depth insights into severe asthma phenotypes, immunology, genetics, and modern biologic therapies, along with evolving treatment strategies based on the latest GINA and NAEPP guidelines.

Led by a multidisciplinary Harvard faculty team, the program covers key topics including aspirin-exacerbated respiratory disease, eosinophilic lung disorders, occupational asthma, obesity-related asthma, and pediatric considerations.

Participants will also explore advanced topics such as precision medicine approaches, emerging biologics, psychiatric comorbidities, and population health management. Interactive case discussions and real-world clinical scenarios enhance practical understanding.

Ideal for pulmonologists, allergists, internal medicine physicians, and ENT specialists, this course equips clinicians with the latest evidence-based tools to manage severe asthma effectively.